{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:38Z","timestamp":1794414458578,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41433-026-04830-5","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:40:11Z","timestamp":1788442811000},"page":"2541-2545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delayed foveal atrophy following early visual improvement after voretigene neparvovec gene therapy in a child"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-4401","authenticated-orcid":false,"given":"Peter","family":"Kiraly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2923-0972","authenticated-orcid":false,"given":"Tsveta","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-137X","authenticated-orcid":false,"given":"Assad","family":"Jalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"4830_CR1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet (Lond, Engl). 2017;390:849\u201360.","journal-title":"Lancet (Lond, Engl)"},{"key":"4830_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 2019;126:1273\u201385.","journal-title":"Ophthalmology"},{"key":"4830_CR3","doi-asserted-by":"crossref","unstructured":"Fischer MD, Simonelli F, Sahni J, Holz FG, Maier R, Fasser C, et al. Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE study. Biomolecules. 2024;14:122.","DOI":"10.3390\/biom14010122"},{"key":"4830_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","volume":"6","author":"WS Gange","year":"2022","unstructured":"Gange WS, Sisk RA, Besirli CG, Lee TC, Havunjian M, Schwartz H, et al. Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated leber congenital amaurosis. Ophthalmol Retin. 2022;6:58\u201364.","journal-title":"Ophthalmol Retin"},{"key":"4830_CR5","doi-asserted-by":"crossref","unstructured":"Reichel FF, Seitz I, Wozar F, Dimopoulos S, Jung R, Kempf M, et al. Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec. Br J Ophthalmol. 2023;107:1331\u20135.","DOI":"10.1136\/bjophthalmol-2021-321023"},{"key":"4830_CR6","doi-asserted-by":"crossref","unstructured":"Kiraly P, Cottriall CL, Taylor LJ, Jolly JK, Cehajic-Kapetanovic J, Yusuf IH, et al. Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center. Biomolecules. 2023;13:1484.","DOI":"10.3390\/biom13101484"},{"key":"4830_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22180-6","volume":"12","author":"F Testa","year":"2022","unstructured":"Testa F, Melillo P, Di Iorio V, Iovino C, Farinaro F, Karali M, et al. Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy. Sci Rep. 2022;12:17637.","journal-title":"Sci Rep"},{"key":"4830_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/bjo-2024-326221","volume":"109","author":"A Daruich","year":"2025","unstructured":"Daruich A, Rateaux M, Batt\u00e9 E, de Vergnes N, Valleix S, Robert MP, et al. 12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy. Br J Ophthalmol. 2025;109:281\u20135.","journal-title":"Br J Ophthalmol"},{"key":"4830_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41433-025-03672-x","volume":"39","author":"P Kiraly","year":"2025","unstructured":"Kiraly P, Ivanova T, Jalil A. Foveal detachment in voretigene neparvovec administration: essential step or avoidable risk? Eye (Lond, Engl). 2025;39:810\u20131.","journal-title":"Eye (Lond, Engl)"},{"key":"4830_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01634-y","volume":"15","author":"A Skorczyk-Werner","year":"2020","unstructured":"Skorczyk-Werner A, Niedziela Z, Stopa M, Krawczy\u0144ski MR. Novel gene variants in Polish patients with Leber congenital amaurosis (LCA). Orphanet J Rare Dis. 2020;15:345.","journal-title":"Orphanet J Rare Dis"},{"key":"4830_CR11","doi-asserted-by":"crossref","unstructured":"Gerhardt MJ, Priglinger CS, Rudolph G, Hufendiek K, Framme C, J\u00e4gle H, et al. Gene therapy with voretigene neparvovec improves vision and partially restores electrophysiological function in pre-school children with leber congenital amaurosis. Biomedicines. 2022;11:103.","DOI":"10.3390\/biomedicines11010103"},{"key":"4830_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/iovs.63.2.13","volume":"63","author":"F Testa","year":"2022","unstructured":"Testa F, Murro V, Signorini S, Colombo L, Iarossi G, Parmeggiani F, et al. RPE65-associated retinopathies in the Italian population: a longitudinal natural history study. Invest Ophthalmol Vis Sci. 2022;63:13.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4830_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajo.2018.09.024","volume":"199","author":"DC Chung","year":"2019","unstructured":"Chung DC, Bertelsen M, Lorenz B, Pennesi ME, Leroy BP, Hamel CP, et al. The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene. Am J Ophthalmol. 2019;199:58\u201370.","journal-title":"Am J Ophthalmol"},{"key":"4830_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","volume":"130","author":"K Stingl","year":"2023","unstructured":"Stingl K, Stingl K, Schwartz H, Reid MW, Kempf M, Dimopoulos S, et al. Full-field scotopic threshold improvement after voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy. Ophthalmology. 2023;130:764\u201370.","journal-title":"Ophthalmology"},{"key":"4830_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.omtm.2023.02.006","volume":"28","author":"JB Ducloyer","year":"2023","unstructured":"Ducloyer JB, Pichard V, Mevel M, Galy A, Lefevre GM, Brument N, et al. Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution. Mol Ther Methods Clin Dev. 2023;28:387\u201393.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4830_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100516","volume":"4","author":"IP Seitz","year":"2024","unstructured":"Seitz IP, Wozar F, Ochakovski GA, Reichel FF, Gelisken F, Bartz-Schmidt KU, et al. Dose-dependent progression of chorioretinal atrophy at the injection site after subretinal injection of rAAV2\/8 in nonhuman primates. Ophthalmol Sci. 2024;4:100516.","journal-title":"Ophthalmol Sci"},{"key":"4830_CR17","doi-asserted-by":"crossref","unstructured":"Shu Y, Zhang C, Bi Y, Zhang J. Hyperreflective foci and subretinal fluid predicts microglia activation involved in the breakdown of outer blood-retinal barrier in treatment-na\u00efve patients with diabetic macular edema. Asia Pac J Ophthalmol (Phila). 2025;14:100168.","DOI":"10.1016\/j.apjo.2025.100168"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04830-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04830-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04830-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:09:04Z","timestamp":1794413344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04830-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":17,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4830"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04830-5","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This retrospective, anonymised study was exempt from ethical approval under local Clinical Effectiveness Department protocols and national guidance from the National Code of Clinical Research and the Health Research Authority (HRA). No additional patient consent was required. All procedures were performed before the study was designed, in accordance with local clinical guidelines, and written consent was obtained for all clinically indicated interventions. No new or experimental protocols were used.","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}